Foresite Capital Management III’s Alder Biopharmaceuticals, Inc. ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,393,612
| Closed | -$45.1M | – | 13 |
|
|
2019
Q3 | $45.1M | Sell |
2,393,612
-548,518
| -19% | -$10.3M | 17.24% | 2 |
|
|
2019
Q2 | $34.6M | Hold |
2,942,130
| – | – | 11.36% | 3 |
|
|
2019
Q1 | $40.2M | Hold |
2,942,130
| – | – | 10.45% | 3 |
|
|
2018
Q4 | $30.2M | Hold |
2,942,130
| – | – | 9.9% | 3 |
|
|
2018
Q3 | $49M | Hold |
2,942,130
| – | – | 10.81% | 3 |
|
|
2018
Q2 | $46.5M | Hold |
2,942,130
| – | – | 10.01% | 3 |
|
|
2018
Q1 | $37.4M | Buy |
2,942,130
+95,000
| +3% | +$1.21M | 8.14% | 4 |
|
|
2017
Q4 | $32.6M | Sell |
2,847,130
-95,073
| -3% | -$1.09M | 9.15% | 3 |
|
|
2017
Q3 | $36M | Buy |
2,942,203
+765,000
| +35% | +$9.37M | 9.93% | 2 |
|
|
2017
Q2 | $24.9M | Buy |
2,177,203
+547,981
| +34% | +$6.27M | 8.14% | 3 |
|
|
2017
Q1 | $33.9M | Buy |
1,629,222
+894
| +0.1% | +$18.6K | 13.01% | 2 |
|
|
2016
Q4 | $33.9M | Buy |
1,628,328
+42,645
| +3% | +$887K | 14.72% | 3 |
|
|
2016
Q3 | $52M | Sell |
1,585,683
-14,500
| -0.9% | -$475K | 24.29% | 2 |
|
|
2016
Q2 | $40M | Buy |
1,600,183
+321,613
| +25% | +$8.03M | 27.42% | 1 |
|
|
2016
Q1 | $31.3M | Buy |
1,278,570
+1,048,675
| +456% | +$25.7M | 24.23% | 1 |
|
|
2015
Q4 | $7.59M | Buy |
+229,895
| New | +$7.59M | 6.73% | 3 |
|